Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Xencor, Pfizer Enter Antibody Tech Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News

Xencor, Pfizer Enter Antibody Tech Pact

Pfizer has entered into a technology license and evaluation agreement with Xencor, Inc. to optimize its therapeutic monoclonal antibodies.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Pfizer has entered into a technology license and evaluation agreement with Xencor, Inc. to optimize its therapeutic monoclonal antibodies. Pfizer will apply Xencor’s Xtend antibody half-life prolongation technology and XmAb ADCC enhancing technology for to its antibody drug candidates. Pfizer will have access to Xencor’s antibody technology for a non-exclusive research period for use in several of its discovery projects.

Pfizer has also taken a commercial license to Xencor’s technology for one program. Xencor will receive an upfront payment from Pfizer and is eligible to receive success-based payments upon commercialization of products using the technology. Financial details were not disclosed.

“We are delighted that a world-class leader in the antibody space such as Pfizer will be broadly investigating the use of Xencor’s antibody optimization technology within its R&D organization to potentially enhance specific properties of its therapeutic antibody drug candidates,” commented Bassil Dahiyat, Ph.D., Xencor’s chief executive officer.

“The ability to enhance the pharmaceutical properties of antibody drug molecules and customize this class of drugs for specific therapeutic settings is a central differentiating factor which Xencor will continue to pioneer,” commented James Posada, Ph.D., MBA, Xencor’s acting chief business officer.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters